ArticlePeerJ2025
Survival benefit from adjuvant chemoradiotherapy in local advanced gastric cancer without accurate D2 confirmation: a real-world retrospective study (TJ-ARK01).
Article in PeerJ, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The role of adjuvant chemoradiotherapy (CRT) is controversial following D2 dissection in advanced gastric cancer. Also, the extent of "D2 surgery" varied geographically due to the diversity in surgical techniques of radical lymphadenectomy and pathological accuracy in detecting positive lymph nodes detection. The purpose was to explore the role of adjuvant chemoradiation for gastric cancer and focus on patient stratification strategy. We retrospectively collected information of patients underwent surgery in Tongji Medical Cancer Center from January 2013 to December 2017 (2,489 in total). Propensity score match was applied to the chemotherapy (CT) group enrollment with well-balanced clinicopathological distributions. In total, 162 and 166 eligible patients were recruited into CT and CRT groups, nearly 75% diagnosed with advanced stage. The median follow-up duration was 61.3 months (4.0 to 109.0 months), 201 recurrence events occurred and 194 deaths events occurred. The 5-year disease-free-survival (DFS) rates were 32.0% in CT group and 44.0% in CRT group (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.